Catalyst Crew Technologies Corp. has appointed Dr. Kevin Rodan Levy as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and Sole Director, effective February 17, 2026. The leadership transition follows the resignation of the company's prior officers and directors, as disclosed in a Form 8-K filed with the U.S. Securities and Exchange Commission. Dr. Rodan brings experience in healthcare operations, technology-enabled service platforms, and executive management to his new role.
Since 2021, Dr. Rodan has served as Chief Executive Officer of Grupo Casamed 18 C.A., where he has been involved in healthcare delivery management and organizational development initiatives. He has also led EmpleUp, a technology-focused human capital and recruitment platform. The appointment aligns with the company's strategic transition toward artificial intelligence-enabled healthcare technology solutions. Dr. Rodan's background combines clinical medical training with operational leadership and exposure to emerging technology applications within healthcare systems.
His experience is expected to support the company's focus on developing scalable digital health solutions for emerging markets, with initial emphasis on Latin America. "I am honored to lead Catalyst Crew Technologies Corp. at this pivotal stage in its evolution," said Dr. Rodan. "Our focus is on disciplined execution of the Company's strategic transition into AI-enabled healthcare solutions, with particular emphasis on scalable platforms that address access and efficiency challenges in emerging markets."
The company intends to pursue opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms designed to improve access, efficiency, and care coordination. Through technology development initiatives, strategic partnerships, and targeted acquisitions, Catalyst Crew Technologies aims to build an integrated healthcare technology platform positioned to address the growing demand for modernized healthcare delivery systems. For more details about the company, visit https://catalystcrewai.com, or access its official filings through the https://www.sec.gov website.
The company is a development-stage enterprise that has not generated revenues from its newly announced business direction and cautions that forward-looking statements involve risks and uncertainties. This leadership change represents a significant strategic pivot for Catalyst Crew Technologies as it positions itself in the competitive digital health market. The appointment of a single individual to all key leadership positions indicates a streamlined approach to executing the company's new direction, though it also concentrates decision-making authority. The focus on emerging markets, particularly Latin America, addresses a significant gap in healthcare access and technology adoption in regions with growing populations and increasing healthcare needs.
Dr. Rodan's combined background in clinical medicine and technology leadership could provide valuable perspective in developing solutions that balance technological innovation with practical healthcare delivery requirements. The company's emphasis on AI-enabled platforms reflects broader industry trends toward data-driven healthcare solutions that can scale efficiently. However, as a development-stage company without revenue from this new direction, Catalyst Crew Technologies faces the challenge of securing funding, developing viable products, and establishing market presence in a competitive sector where many established players are already investing heavily in similar technologies.
